

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02342 A1

(51) International Patent Classification⁷: C07C 229/50,
229/36, A61K 31/195, 31/196, A61P 25/28, C07C 255/47,
255/42, 255/44, C07D 235/02, 233/78

(21) International Application Number: PCT/CA00/00770

(22) International Filing Date: 30 June 2000 (30.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,276,798 30 June 1999 (30.06.1999) CA

(71) Applicant (for all designated States except US): **IGT
PHARMA INC.** [CA/CA]; 2386 East Mall, No. 311,
Vancouver, British Columbia V6T 1Z3 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CURRY, Kenneth**
[CA/CA]; 2438 West 49th Avenue, Vancouver, British
Columbia V6M 2V3 (CA).

(74) Agent: **MBM & CO.**; P.O. Box 809, Station B, Ottawa,
Ontario K1P 5P9 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/02342 A1

(54) Title: 2-AMINOINDANE ANALOGS



(57) **Abstract:** The present invention relates to thera-
peutically active 2-aminoindane analogs of formula (I).
Also provided is a method of preparing compounds of
formula (I), and pharmaceutical compositions compris-
ing the compounds. The novel compounds act as modu-
lators of metabotropic glutamate receptors and, as such,
are useful in treating diseases of the central nervous sys-
tem related to the metabotropic glutamate receptor sys-
tem.

2-AMINOINDANE ANALOGS

FIELD OF THE INVENTION

- 5 This invention pertains to therapeutically active 2-aminoindane analogs, a method for preparing the same, pharmaceutical compositions comprising the compounds and a method of treating diseases of the Central Nervous System (CNS) therewith.

BACKGROUND OF THE INVENTION

- 10 The acidic amino acid L-glutamate is recognized as the major excitatory neurotransmitter in the CNS. The receptors that respond to L-glutamate are called excitatory amino acid receptors. The excitatory amino acid receptors are thus of great physiological importance, playing a role in a variety of physiological processes, such as long-term potentiation (learning and memory), the development of synaptic plasticity, motor control, respiratory
15 and cardiovascular regulation, and sensory perception.

- Excitatory amino acid receptors are classified into two general types and both are activated by L-glutamate and its analogs. Receptors activated by L-glutamate that are directly coupled to the opening of cation channels in the cell membrane of the neurons are termed
20 "ionotropic." This type of receptor has been subdivided into at least three subtypes, which are defined by the depolarizing actions of the selective agonists *N*-Methyl-D-aspartate (NMDA), α -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and Kainic acid (KA).

- 25 The second general type of receptor is the G-protein or second messenger-linked "metabotropic" excitatory amino acid receptor. This second type is coupled to multiple second messenger systems that lead to enhanced phosphoinositide hydrolysis, activation of phospholipase D, increases or decreases in cAMP formation, and changes in ion channel function (Schoepp and Conn, *Trends in Pharmacological Science*, 14:13, 1993). Both types
30 of receptors appear not only to mediate normal synaptic transmission along excitatory pathways but also to participate in the modification of synaptic connections during development and throughout life.

So far eight different clones of the G-protein-coupled mGluRs have been identified (Knopfel *et al.*, 1995, *J. Med. Chem.*, 38, 1417-1426). These receptors function to modulate the presynaptic release of L-glutamate, and the postsynaptic sensitivity of the neuronal cell to L-glutamate excitation. Based on pharmacology, sequence homology and the signal transduction pathway that they activate, the mGluRs have been subclassified into three groups. The mGluR₁ and mGluR₅ receptors form group I. They are coupled to hydrolysis of phosphatidylinositol (PI) and are selectively activated by (*RS*)-3,5-dihydroxyphenylglycine (Brabet *et al.*, *Neuropharmacology*, 34, 895-903, 1995). Group II comprises mGluR₂ and mGluR₃ receptors. They are negatively coupled to adenylate cyclase and are selectively activated by (*2S,1'R,2'R,3'R*)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV; Hayashi *et al.*, *Nature*, 366, 687-690, 1993). Finally, the mGluR₄, mGluR₆, mGluR₇ and mGluR₈ receptors belong to group III. They are also negatively coupled to adenylate cyclase and are selectively activated by (*L*)-2-amino-4-phosphonobutyric acid (L-AP4; Knopfel *et al.*, 1995, *J. Med. Chem.*, 38, 1417-1426).

Agonists and antagonists of these receptors are believed useful for the treatment of acute and chronic neurodegenerative conditions, and as antipsychotic, anticonvulsant, analgesic, anxiolytic, antidepressant, and anti-emetic agents. Antagonists and agonists of neural receptors are classified as selective for a particular receptor or receptor subtype, or as non-selective. Antagonists may also be classified as competitive or non-competitive. While competitive and non-competitive antagonists act on the receptors in a different manner to produce similar results, selectivity is based upon the observations that some antagonists exhibit high levels of activity at a single receptor type, and little or no activity at other receptors. In the case of receptor-specific diseases and conditions, the selective agonists and antagonists are of the most value.

Compounds such as L-Glutamic acid, Quisqualic acid and Ibotenic acid are known to act as non-selective agonists on the mGluRs, while selective ionotropic glutamate receptor agonists such as NMDA, AMPA and kainate have little effect on these receptors. Recently a few compounds without activity at the ionotropic glutamate receptors but with activity at the metabotropic receptors have been identified. These include *trans*-ACPD (*trans*-

(1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid), the partial agonist L-AP3 (L-2-amino-3-phosphonopropionic acid; Palmer, E., Monaghan, D. T. and Cotman, C. W. *Eur. J. Pharmacol.* 166, 585-587, 1989; Desai, M. A. and Conn, P. J. *Neuroscience Lett.* 109, 157-162, 1990; Schoepp, D. D. *et al.*, *J. Neurochemistry* 56, 1789-1796, 1991; 5 Schoepp D. D. and Johnson B. G. *J. Neurochemistry* 53, 1865-1913, 1989), L-AP4 (L-2-amino-4-phosphonobutyric acid) which is an agonist at the mGluR₄ receptor (Thomsen C. *et al.*, *Eur. J. Pharmacol.* 227, 361-362, 1992) and some of the isomers of CCG (2-(carboxycyclopropyl)glycines) especially L-CCG-I and L-CCG-II (Hayashi, Y. *et al.*, *Br. J. Pharmacol.* 107, 539-543, 1992).

10

Very few selective antagonists at the mGluRs have been reported. However some phenylglycine derivatives, *S*-4CPG (*S*-4-carboxyphenylglycine), *S*-4C3HPG (*S*-4-carboxy-3-hydroxyphenylglycine) and *S*-MCPG (*S*- α -methyl-4-carboxyphenylglycine) have been reported to antagonize *trans*-ACPD- stimulated phosphoinositide hydrolysis and thus 15 possibly act as antagonists at mGluR₁ and mGluR₃ subtypes (Thomsen, C. and Suzdak, P. *Eur. J. Pharmacol.* 245, 299, 1993).

Research directed towards mGluRs is beginning to show that mGluRs may be implicated in a number of normal as well as pathological mechanisms in the brain and spinal cord. 20 For example, activation of these receptors on neurons can: influence levels of alertness, attention and cognition; protect nerve cells from excitotoxic damage resulting from ischemia, hypoglycemia and anoxia; modulate the level of neuronal excitation; influence central mechanisms involved in controlling movement; reduce sensitivity to pain; reduce levels of anxiety.

25

The use of compounds active at the mGluRs for the treatment of epilepsy is corroborated by investigations of the influence of *trans*-ACPD on the formation of convulsions (Sacaan and Schoepp, *Neuroscience Lett.* 139, 77, 1992) and that phosphoinositide hydrolysis mediated via mGluR is increased after kindling experiments in rats (Akiyama *et al.* *Brain Res.* 569, 71, 1992). Trans-ACPD has been shown to increase release of dopamine in the 30 rat brain, which indicates that compounds acting on the mGluRs might be usable for the

treatment of Parkinson's disease and Huntington's Chorea (Sacaan *et al.*, *J. Neurochemistry* 59, 245, 1992).

Trans-ACPD has also been shown to be a neuroprotective agent in a medial cerebral artery occlusion (MCAO) model in mice (Chiamulera *et al.* *Eur. J. Pharmacol.* 215, 353, 1992), and it has been shown to inhibit NMDA-induced neurotoxicity in nerve cell cultures (Koh v, *Proc. Natl. Acad. Sci. USA* 88, 9431, 1991). The mGluR-active compounds are also implicated in the treatment of pain. This is proved by the fact that antagonists at the mGluRs antagonize sensory synaptic response to noxious stimuli of thalamic neurons (Eaton, S. A. *et al.*, *Eur. J. Neuroscience*, 5, 186, 1993).


The use of compounds active at the mGluRs for treatment of neurological diseases such as senile dementia have also been indicated by the findings of Zheng and Gallagher, *Neuron* 9, 163, 1992 and Bashir *et al.* (*Nature* 363, 347, 1993) who demonstrated that activation of mGluRs is necessary for the induction of long-term potentiation (LTP) in nerve cells (septal nucleus, hippocampus) and the finding that long-term depression is induced after activation of mGluRs in cerebellar granule cells (Linden *et al.* *Neuron* 7, 81, 1991).

Thus compounds that demonstrate either activating or inhibiting activity at mGluRs have therapeutic potential for the treatment of neurological disorders. These compounds have application as new drugs to treat both acute and chronic neurological disorders, such as stroke and head injuries; epilepsy; movement disorders associated with Parkinson's disease and Huntington's chorea; pain; anxiety; AIDS dementia; and Alzheimer's disease. Since the mGluRs can influence levels of alertness, attention and cognition; protect nerve cells from excitotoxic damage resulting from ischemia, hypoglycemia and anoxia; modulate the level of neuronal excitation; influence central mechanisms involved in controlling movement; reduce sensitivity to pain; and reduce levels of anxiety, these compounds can also be used to influence these situations and also find use in learning and memory deficiencies such as senile dementia. mGluRs may also be involved in addictive behaviour, alcoholism, drug addiction, sensitization and drug withdrawal (*Science*, 280:2045, 1998), so compounds acting at mGluRs might also be used to treat these disorders.

The current pharmaceutical options for treating neurological disorders tend to be very general and non-specific in their actions in that, although they may reduce the clinical symptoms associated with a specific neurological disorder, they may also negatively impact normal function of the central nervous system of patients. Thus new cellular targets and drugs that are more specific in their actions require to be identified and developed and thus a need remains for chemical compounds that demonstrate specific binding characteristics towards mGluRs.

10 SUMMARY OF THE INVENTION

An object of the present invention is to provide 2-aminoindane analogs that demonstrate activity at the various metabotropic glutamate receptors. In accordance with an aspect of the invention, there is provided a compound of formula (I):



15

stereoisomers thereof, or pharmaceutically acceptable salts or hydrates thereof, wherein:

R1, and **R2** are selected from the group comprising:

20 1) H; or:

2) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfino, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, where $n = 1, 2, 3, 4, 5$, or 6 ; or:

25

X is an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol.

Y is a basic group selected from the group comprising 1° amino, 2° amino, 3° amino, quaternary ammonium salts, aliphatic 1° amino, aliphatic 2° amino, aliphatic 3° amino, aliphatic quaternary ammonium salts, aromatic 1° amino, aromatic 2° amino, aromatic 3° amino, aromatic quaternary ammonium salts, imidazol, guanidino, boronoamino, allyl, urea, thiourea ;

m is 0, 1.

R3, R4, R5, R6 are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl or acceptable esters thereof,

or a salt thereof with a pharmaceutically acceptable acid or base.

DETAILED DESCRIPTION OF THE INVENTION

The terms and abbreviations used in the instant examples have their normal meanings unless otherwise designated. For example "°C" refers to degrees Celsius; "N" refers to normal or normality; "mmol" refers to millimole or millimoles; "g" refers to gram or grams; "ml" means milliliter or milliliters; "M" refers to molar or molarity; "p-" refers to para, "MS" refers to mass spectrometry; "IR" refers to infrared spectroscopy; and "NMR" refers to nuclear magnetic resonance spectroscopy.

As would be understood by the skilled artisan, throughout the synthesis of the compounds of Formula I it may be necessary to employ an amino-protecting group or a carboxy-protecting group in order to reversibly preserve a reactively susceptible amino or carboxy functionality while reacting other functional groups on the compound.

Examples of such amino-protecting groups include formyl, trityl, phthalimido, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl, and urethane-type blocking groups such as benzyloxycarbonyl, 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl,


- 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, *t*-butoxycarbonyl, 2-(4-xenyl)-isopropoxycarbonyl,
- 5 1,1-diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl, 2-phenylprop-2-yloxycarbonyl, 2-(*p*-toluyl)-prop-2-yloxycarbonyl, cyclopentanyloxy-carbonyl, 1-methylcyclopentanyloxycarbonyl, cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycarbonyl, 2-methylcyclohexanyloxycarbonyl, 2-(4-toluylsulfonyl)-ethoxycarbonyl,
- 10 2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl, fluorenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5-benzisoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl,
- 15 4-(decyloxy)benzyloxycarbonyl, isobornyloxycarbonyl, 1-piperidyloxycarbonyl and the like; benzoylmethylsulfonyl group, 2-nitrophenylsulfenyl, diphenylphosphine oxide and like amino-protecting groups. The species of amino-protecting group employed is not critical so long as the derivatized amino group is stable to the condition of subsequent reaction(s) on other positions of the intermediate molecule and can be selectively removed
- 20 at the appropriate point without disrupting the remainder of the molecule including any other amino-protecting group(s). Preferred amino-protecting groups are *t*-butoxycarbonyl (*t*-Boc), allyloxycarbonyl and benzyloxycarbonyl (CbZ). Further examples of these groups are found in E. Haslam, *Protecting Groups in Organic Chemistry*, (J. G. W. McOmie, ed., 1973), at Chapter 2; and T. W. Greene and P. G. M. Wuts, *Protective Groups in Organic*
- 25 *Synthesis*, (1991), at Chapter 7.

- Examples of such carboxy-protecting groups include methyl, *p*-nitrobenzyl, *p*-methylbenzyl, *p*-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl,
- 30 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxybenzhydryl, 2,2',4,4'-tetramethoxybenzhydryl, *t*-butyl, *t*-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4''-trimethoxytrityl, 2-phenylprop-2-yl, trimethylsilyl,

t-butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl, β -(di(*n*-butyl)methylsilyl)ethyl, *p*-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, 1-(trimethylsilylmethyl)prop-1-en-3-yl and like moieties. Preferred carboxy-protecting groups are allyl, benzyl and *t*-butyl. Further examples of these groups are found in E.

5 Haslam, *supra*, at Chapter 5; and T. W. Greene and P. G. M. Wuts, *supra*, at Chapter 5.

The present invention provides a compound of the formula I:



10 Stereoisomers thereof, or pharmaceutically acceptable salts or hydrates thereof, wherein:

R1, and R2 are selected from the group comprising:

15 1) H

2) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfino, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, where $n = 1, 2, 3, 4, 5$, or 6 ; or

20

X is an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol.

25 Y is a basic group selected from the group comprising 1° amino, 2° amino, 3° amino, quaternary ammonium salts, aliphatic 1° amino, aliphatic 2° amino, aliphatic 3° amino, aliphatic quaternary ammonium salts, aromatic 1° amino, aromatic 2° amino, aromatic 3°

amino, aromatic quaternary ammonium salts, imidazol, guanidino, boronoamino, allyl, urea, thiourea ;

m is 0, 1.

5

R3, R4, R5, R6 are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl or pharmaceutically acceptable esters or salts thereof,

10

In one embodiment of the present invention a compound of formula (I) is provided, wherein:

R1 is CO₂H, or CH₂CO₂H; **R2** is H; **X** is CO₂H; and **Y** is NH₂


15

In another embodiment of the present invention a compound of formula (I) is provided, wherein:

R1 is H; **R2** is CO₂H or CH₂CO₂H; **X** is CO₂H; and **Y** is NH₂

20

Compounds of the present invention include, but are not limited to the following exemplary molecules:



While all of the compounds of Formula I are believed to demonstrate activity at the metabotropic glutamate receptors (mGluRs), certain groups of Formula I compounds are more preferred for such use.

- 5 As noted supra, this invention includes the pharmaceutically acceptable salts of the compounds defined by Formula I. A compound of this invention can possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of organic and inorganic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

10

The term "pharmaceutically acceptable salt" as used herein, refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a pharmaceutically acceptable mineral or organic acid or an
15 organic or inorganic base. Such salts are known as acid addition and base addition salts.

- Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as *p*-toluenesulfonic acid, methanesulfonic acid, oxalic acid, *p*-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic
20 acid, and the like. Examples of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate,
25 sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ -hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like.

30

Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.

- 5 Salts of amine groups may also comprise quarternary ammonium salts wherein the amino nitrogen carries a suitable organic group such as an alkyl, alkenyl, alkynyl, or aralkyl moiety.

Base addition salts include those derived from inorganic bases, such as ammonium or
10 alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. The potassium and sodium salt forms are particularly preferred.

15

It should be recognized that the particular counterion forming a part of any salt of this invention is usually not of a critical nature, as long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.

20

This invention further encompasses the pharmaceutically acceptable solvates of the compounds of Formula I. Many of the Formula I compounds can combine with solvents such as water, methanol, ethanol and acetonitrile to form pharmaceutically acceptable solvates such as the corresponding hydrate, methanolate, ethanolate and acetonitrilate.

25

The compounds of the present invention have multiple asymmetric (chiral) centers. As a consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All asymmetric forms, individual isomers and combinations
30 thereof, are within the scope of the present invention.

The prefixes "R" and "S" are used herein as commonly used in organic chemistry to denote the absolute configuration of a chiral center, according to the Cahn-Ingold-Prelog system. The stereochemical descriptor *R* (*rectus*) refers to that configuration of a chiral center with a clockwise relationship of groups tracing the path from highest to second-lowest priorities when viewed from the side opposite to that of the lowest priority group. The stereochemical descriptor *S* (*sinister*) refers to that configuration of a chiral center with a counterclockwise relationship of groups tracing the path from highest to second-lowest priority when viewed from the side opposite to the lowest priority group. The priority of groups is decided using sequence rules as described by Cahn *et al.*, *Angew. Chem.*, 78, 413-447, 1966 and Prelog, V. and Helmchen, G.; *Angew. Chem. Int. Ed. Eng.*, 21, 567-583, 1982).

In addition to the *R,S* system used to designate the absolute configuration of a chiral center, the older D-L system is also used in this document to denote relative configuration, especially with reference to amino acids and amino acid derivatives. In this system a Fischer projection of the compound is oriented so that carbon-1 of the parent chain is at the top. The prefix "D" is used to represent the relative configuration of the isomer in which the functional (determining) group is on the right side of the carbon atom at the chiral center and "L", that of the isomer in which it is on the left.

As would be expected, the stereochemistry of the Formula I compounds is critical to their potency as agonists or antagonists. The relative stereochemistry is preferably established early during synthesis, which avoids stereoisomer separation problems later in the process. Subsequent synthetic steps then employ stereospecific procedures so as to maintain the preferred configuration. The preferred methods of this invention are the methods employing those preferred compounds.


Non-toxic metabolically labile esters and amides of compounds of Formula I are ester or amide derivatives of compounds of Formula I that are hydrolyzed *in vivo* to afford said compounds of Formula I and a pharmaceutically acceptable alcohol or amine. Examples of metabolically labile esters include esters formed with (C₁-C₆) alkanols in which the alkanol moiety may be optionally substituted by a (C₁-C₈) alkoxy group, for example methanol,

ethanol, propanol and methoxyethanol. Examples of metabolically labile amides include amides formed with amines such as methylamine.


Preparation Of Compounds Of Formula (I):

- 5 According to another aspect, the present invention provides a process for the preparation of a compound of Formula I, or a pharmaceutically acceptable metabolically-labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which comprises:

(a) hydrolyzing a compound of formula (IIa) or (IIb) :



(IIa)



(IIb)


10

wherein:


R1, R2, R3, R4, R5 and R6 are as defined above. R7 is a hydrogen atom or an acyl group. Preferred functional groups for R7 are hydrogen and (C₂-C₆) alkanoyl groups, such as acetyl; or

15

(b) hydrolyzing a compound of formula (IIIa) or (IIIb):



(IIIa)




(IIIb)

wherein:


R1, R2, R3, R4, R5 and R6 are as defined above, **R8** and **R9** are each independently
 5 represent a hydrogen atom, a (C₂-C₆) alkanoyl group, a (C₁-C₄) alkyl group, a (C₃-C₄)
 alkenyl group or a phenyl (C₁-C₄) alkyl group, wherein the phenyl is unsubstituted or
 substituted by halogen, (C₁-C₄) alkyl or (C₁-C₄) alkoxy, or a salt thereof; or

(c) deprotecting a compound of formula (IVa) or (IVb):

10



(IVa)



(IVb)

15 wherein:

R1, R2, R3, R4, R5 and R6 are as defined above and **R10** is a hydrogen atom or a
 carboxyl protecting group, or a salt thereof, and **R11** is a hydrogen atom or a nitrogen
 protecting group;

20 whereafter, if necessary and/or desired, the following steps are carried out:

- (i) resolving the compound of Formula I;
- (ii) converting the compound of Formula I into a non-toxic metabolically labile ester or
 amide thereof; and/or;
- (iii) converting the compound of Formula I or a non-toxic metabolically labile ester or
 25 amide thereof into a pharmaceutically acceptable salt thereof.

Compounds of formulae (II), (III) and (IV), wherein at least one of R3, R4, R5 and R6 is other than H may be prepared from the compounds of formula (II), (III) and (IV) respectively, wherein R3, R4, R5 and R6 is H, using standard reactions known to a person skilled in the art. For example: electrophilic substitution with appropriate electrophile, Friedel-Crafts alkylation or acylation, followed by further manipulations of the formed products within the knowledge of a worker skilled in the art.

The protection of carboxylic acid and amine groups is generally described in McOmie, *Protecting Groups in Organic Chemistry*, Plenum Press, NY, 1973, and Greene and Wuts, *Protective Groups in Organic Synthesis*, 2nd. Ed., John Wiley & Sons, NY, 1991. Examples of carboxy protecting groups include alkyl groups such as methyl, ethyl, *t*-butyl and *t*-amyl; aralkyl groups such as benzyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl and trityl; silyl groups such as trimethylsilyl and *t*-butyldimethylsilyl; and allyl groups such as allyl and 1-(trimethylsilylmethyl)prop-1-en-3-yl. Examples of amine protecting groups include acyl groups, such as groups of formula $-C(O)R_{11}$ in which **R11** represents (C₁-C₆) alkyl, (3-10C) cycloalkyl, phenyl (C₁-C₆) alkyl, phenyl (C₁-C₆) alkoxy, or a (C₃-C₁₀) cycloalkoxy, wherein a phenyl group may optionally be substituted by one or two substituents independently selected from amino, hydroxy, nitro, halogeno, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, carboxy, (C₁-C₆) alkoxycarbonyl, carbamoyl, (C₁-C₆) alkanoylamino, (C₁-C₆) alkylsulphonylamino, phenylsulphonylamino, toluenesulphonylamino, and (C₁-C₆) fluoroalkyl.

25

The compounds of Formula II are conveniently hydrolyzed in the presence of an acid, such as hydrochloric acid or sulfuric acid, or a base, such as an alkali metal hydroxide, for example sodium hydroxide. The hydrolysis is conveniently performed in an aqueous solvent such as water and at a temperature in the range from 50 ° to 200 °C.


30

The compounds of Formula III are conveniently hydrolyzed in the presence of a base, for example an alkali metal hydroxide such as lithium, sodium or potassium hydroxide, or an


alkaline earth metal hydroxide such as barium hydroxide. Suitable reaction media include water. The temperature is conveniently in the range from 50 ° to 150 °C.

The compounds of Formula IV may be deprotected by conventional methods. Thus, an alkyl carboxyl protecting group may be removed by hydrolysis. The hydrolysis may conveniently be performed by heating the compound of Formula IV in the presence of either a base, for example an alkali metal hydroxide such as lithium, sodium or potassium hydroxide, or an alkaline metal hydroxide, such as barium hydroxide, or an acid such as hydrochloric acid. The hydrolysis is conveniently performed at a temperature in the range from 10 ° to 300 °C. An aralkyl carboxyl-protecting group may conveniently be removed by hydrogenolysis. The hydrogenolysis may conveniently be effected by reacting the compound of Formula IV with hydrogen in the presence of a Group VIII metal catalyst, for example a palladium catalyst such as palladium on charcoal. Suitable solvents for the reaction include alcohols such as ethanol. The reaction is conveniently performed at a temperature in the range from 0 ° to 100 °C. An acyl amine protecting group is also conveniently removed by hydrolysis, for example as described for the removal of an alkyl carboxyl protecting group.

The compounds of Formula (IIa) and (IIb) may be prepared by reacting compounds of formula (Va) and (Vb) respectively:



(Va)




(Vb)


wherein: **R1**, **R2**, **R3**, **R4**, **R5** and **R6** are as defined above; with an alkali metal cyanide, such as lithium, sodium or potassium cyanide, and either ammonium carbonate in an aqueous alcohol, such as aqueous ethanol, or with an ammonium halide, such as ammonium chloride, conveniently in the presence of ultrasound. If the reaction is

conducted with ammonium carbonate, the reaction is conveniently performed at a temperature in the range from 35 °C to 150 °C. If desired, the compounds of Formula II may then be alkylated, for example using a compound of formula **RCl**, wherein: **R** is (C₁-C₆) straight or branched chain alkyl, or (C₁-C₆) alkanoyl group. As described in more detail hereinafter, the alkylated compounds may be readily separated into their diastereomers. If the reaction is conducted with an ammonium halide in the presence of ultrasound, the ammonium halide is mixed with chromatography grade alumina in the presence of a suitable diluent such as acetonitrile. The mixture is then irradiated with ultrasound, whereafter the compound of Formula V is added, and the mixture is again irradiated. The alkali metal cyanide is then added, followed by further irradiation with ultrasound.

Individual isomers of compounds of Formula (IIa) and (IIb) may be made by reacting a compound of the Formula V with the stereoisomers of the chiral agent (S)- and (R)-phenylglycinol and a reactive cyanide such as trimethylsilyl cyanide to form the intermediate compounds of Formula (VIa) or (VIb), that can be further hydrolysed to give the desired products.



(VIa)




(VIb)

20

The compounds of Formula III may be prepared by reacting a compound of Formula V with an alkali metal cyanide, such as lithium, sodium or potassium cyanide, and ammonium carbonate or ammonium carbamate. Common solvents include alcohols, such as methanol, aqueous methanol and aqueous ethanol. Conveniently the reaction is

performed at a temperature in the range of from 10° to 150 °C. If desired, the compounds of Formula III may then be alkylated, for example using an appropriate alkyl, aryl or acyl chloride.


- 5 The compounds of Formula (Va) are either commercially available or may be prepared using standard procedures known to a person skilled in the relevant art. For example; compounds of formula (Va) can be prepared from compounds of Formula VII, either by hydrolysis or by alkylation followed by hydrolysis of the resulting compounds.
wherein: R can be any carboxyl-protecting group as previously described above.



VII

10

Compounds of Formula VII may be prepared from compounds of Formula VIII by Dieckmann cyclization:




VIII

15

Compounds of Formula VIII may be prepared by esterification of compounds of Formula IX:


20



5

Compounds of Formula IX may be formed from compound (X) by hydrolysis in aqueous HCl.

10



Compounds of formulae (VII), (VII), (IX) and (X) are either commercially available or may be prepared using standard procedures known to a person skilled in the art. Compounds of formulae (VII), (VII), (IX) and (X), wherein at least one of R3, R4, R5 and R6 is other than H may be prepared from the compounds of formulae (VII), (VII), (IX) and (X) respectively, wherein R3, R4, R5 and R6 is H, via standard reactions known to a person skilled in the art. For example: electrophilic substitution with appropriate electrophile, Friedel-Crafts alkylation or acylation, followed by further manipulations of the formed products within the knowledge of a worker skilled in the art.

The compounds of formula (Vb) may be prepared by reacting a compound of formula (Va) with Wittig salt such as (alkoxy methyl)triphenylphosphonium halide in the presence of alkali metal salt of bis (trimethylsilyl) amine or by reacting a compound of formula (Va) with Wittig reagent such as $\text{Ph}_3\text{P}=\text{CHOCH}_3$, followed by reaction with trimethylsilyl halide.

Compounds of formulae (Va), and (Vb), wherein at least one of R3, R4, R5 and R6 is other than H may be prepared from the compounds of formula (Va) and (Vb) respectively, wherein R3, R4, R5 and R6 is H, using standard reactions known to a person skilled in the art. For example: electrophilic substitution with appropriate electrophile, Friedel-Crafts alkylation or acylation, followed by further manipulations of the formed products within the knowledge of a worker skilled in the art.

Many of the intermediates described herein, for example the compounds of Formula II, III and IV, are believed to be novel, and are provided as further aspects of the invention.

Biological and Therapeutic Activity Of Compounds Of Formula (I)

The compounds of formula I of the present invention exhibit agonists or antagonists activity toward certain metabotropic glutamate receptors (mGluRs). Therefore, another aspect of the present invention provides a method of modulating the activity of mGluRs in mammals, which comprises administering to a mammal requiring modulated excitatory amino acid neurotransmission a pharmacologically-effective amount of a compound of Formula I. The term "pharmacologically-effective amount" is used to represent an amount of the compound of the present invention that is capable of affecting the mGluRs. By modulating mGluR activity, a compound of the present invention is acting as an agonist or antagonist of mGluR. When a compound of the present invention acts as an agonist, the interaction of the compound with the excitatory amino acid receptor mimics the response of the interaction of this receptor with its natural ligand, (i.e. L-Glutamic acid). When a compound of the invention acts as an antagonist, the interaction of the compound with the excitatory amino acid receptor blocks or attenuates the response of the interaction of this receptor with its natural ligand, (i.e. L-Glutamic acid).

The particular dose of compound administered according to the present invention will, of course, be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and similar considerations. The compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, or intranasal routes. Alternatively, the compound may be administered by continuous infusion. A typical daily dose will contain from about 0.001 mg/kg to about 100 mg/kg of the active compound of this invention. Preferably, daily doses will be about 0.05 mg/kg to about 50 mg/kg, more preferably from about 0.1 mg/kg to about 20 mg/kg.

A variety of physiological functions have been shown to be subject to influence by excessive or inappropriate stimulation of excitatory amino acid transmission. The Formula I compounds of the present invention are believed (through their interactions at the mGluRs) to have the ability to treat a variety of neurological disorders in a warm-blooded mammals associated with abnormal excitatory amino acid transmission, including but not limited to acute neurological disorders such as cerebral deficits subsequent to cardiac bypass surgery and grafting, cerebral ischemia (e.g. stroke and cardiac arrest), spinal cord trauma, head trauma, perinatal hypoxia, and hypoglycemic neuronal damage. Similarly, the Formula I compounds of the present invention, through their modulation of mGluR activity are believed to have the ability to treat a variety of chronic neurological disorders, such as Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, AIDS-induced dementia, ocular damage and retinopathy, cognitive disorders, and idiopathic and drug-induced Parkinson's disease. The present invention also provides methods for treating these disorders which comprises administering to a patient in need thereof an effective amount of a compound of Formula I.

The Formula I compounds of the present invention, through their modulation of mGluR activity are also believed to have the ability to treat a variety of other neurological disorders in mammals that are associated with glutamate dysfunction, including muscular spasms, convulsions, migraine headaches, urinary incontinence, psychosis, drug tolerance, withdrawal, and cessation (i.e. opiates, benzodiazepines, nicotine, cocaine, or ethanol), smoking cessation, anxiety and related disorders (e.g. panic attack), emesis, brain edema,

chronic pain, sleep disorders, Tourette's syndrome, attention deficit disorder, and tardive dyskinesia. Therefore, the present invention also provides methods for treating these disorders which comprise administering to a patient in need thereof an effective amount of the compound of Formula I.

5

The Formula I compounds of the present invention, through their modulation of mGluR activity are also believed to have the ability to treat a variety of psychiatric disorders, such as schizophrenia, anxiety and related disorders (e.g. panic attack), depression, bipolar disorders, psychosis, and obsessive compulsive disorders. The present invention also provides methods for treating these disorders which comprises administering to a patient in need thereof an effective amount of a compound of Formula I.

10

Functional Assays Employing Cloned Subtypes of Metabotropic Receptors

The pharmacological properties of the compounds of the present invention can be determined *via* appropriate functional assays using recombinant metabotropic glutamate receptors. For example adenylate cyclase assays or phosphatidylinositol hydrolysis assays, performed using standard procedures, can be used to determine agonist or antagonist activity towards mGluRs.

15

In Vitro Testing:

General *in vitro* assay methods include monitoring of adenylate cyclase activity and phosphatidyl inositol hydrolysis in a cell line that expresses the appropriate mGluR.

20

(a) Adenylate Cyclase Activity

Adenylate cyclase activity is determined in initial experiments in transfected mammalian cells, using standard techniques. See, e.g., N. Adham, *et al.*, Supra; R. L. Weinshank, *et al.* Proc. Natl. Acad. Sci. (USA), 89:3630-3634 (1992), and the references cited therein.

25

Mammalian cells (the cell line AV12-664 is especially preferred) are stably transfected with a plasmid comprising the cloned metabotropic glutamate receptor. The cells are maintained in an appropriate medium, for example one consisting of Dulbecco's Modified Eagle's Medium (DMEM) containing 5% dialyzed fetal calf serum, 10 mM HEPES buffer

30

(pH 7.3), 1 mM sodium pyruvate, 1 mM glutamine, and 200 μ g/mL hygromycin.

For the assay the cells are disassociated from stock culture flasks with trypsin, and plated in 24-well plastic tissue culture dishes (15 mm wells) at a density of 500,000-700,000 cells per well using the same culture medium. After a twenty four hour incubation in a humidified CO₂ incubator, the cell monolayers are washed with buffer (for example Dulbecco's phosphate-buffered saline containing 0.5 mM IBMX and 3 mM glucose) and then incubated in the same buffer at 37 °C for 30 minutes. The monolayers are then washed with six exchanges of buffer.

10

Test compound(s) and forskolin, or forskolin alone, dissolved in buffer, are added after the final wash. After incubating for 20 minutes at 37 °C, 0.5 mL of 8 mM EDTA is added to each well. The plates are then placed in a boiling water bath for about four minutes. The supernatant fluids are recovered from the wells and lyophilized. Cyclic AMP (cAMP) determinations are carried out on the lyophilized samples using commercially available radioimmunoassay kits, following the manufacturer's instructions. The cAMP levels in wells containing test compound(s) are then compared to the forskolin controls.

(b) *Phosphatidylinositol Assay*

Phosphatidylinositol hydrolysis is measured in clonal cell lines (for example AV12) harbouring a plasmid expressing the cloned metabotropic glutamate receptor in response to addition of glutamate agonists, as a functional assay for metabotropic glutamate receptor activity according to D. Schoepp, Trends in Pharmaceutical Sciences, 11:508, 1990.

Twenty four well tissue culture vessels are seeded with approximately 250,000 cells per well in an appropriate medium for example Dulbecco's Minimal Essential Media (D-MEM) (in the absence of glutamic acid) containing 2 mM glutamine and 10% dialyzed fetal calf serum. After 24 hours growth at 37 °C, the media is removed and replaced with fresh media containing four microcuries of [³H]myoinositol per well and the cultures are incubated a further 16 to 20 hours. The media is then removed and the cells in each well are washed with serum free medium containing 10 mM lithium chloride, 10 mM

myoinositol, and 10 mM HEPES (2 × 1 mL washes). After the final wash, 0.5 mL of washing solution is added containing the appropriate concentration(s) of test compound(s).

If the particular assay is also testing antagonists, a ten minutes incubation is performed
5 prior to antagonist induction. Cells are incubated for about one hour at 37 °C. in 95%:5% O₂ :CO₂ or as appropriate for time course. The reactions are terminated by removing media and adding 1 mL of cooled 1:1 acetone:methanol followed by incubation on ice for a minimum of twenty minutes.

10 These extracts are then collected and placed in 1.5 mL centrifuge tubes. Each well is washed with 0.5 mL water and this wash is added to the appropriate extract. After mixing and centrifugation, each aqueous supernatant is processed by chromatography on a QMA SEP-PAK® column, which is prewetted and equilibrated by passing 10 mL of water, followed by 8 mL of 1M triethylammonium hydrogen carbonate (TEAB), followed by 10
15 mL of water through the column.

The assay supernatants containing the water soluble [³H]inositol phosphate are passed over the columns. This is followed by a 10 mL water wash and a 4 mL wash with 0.02 M TEAB to remove [³H]inositol precursors. [³H]inositol phosphate is eluted with 4 mL of
20 0.1 M TEAB into scintillation vials and counted in the presence of scintillation cocktail. Total protein in each sample is measured using standard techniques. Measurements are taken as the amount of [³H]inositol phosphate released per milligram of protein.

The assays are carried out in the absence and in the presence of the compound being tested. The measurements of [³H]inositol phosphate per milligram of protein are compared in
25 order to confirm agonist and antagonist activity of the compound being tested.

These types of assays, employing cell lines expressing different subtype of cloned metabotropic receptors, may be used to determine which compounds have selective affinity in that they modulate one subtype of receptor with a greater activity than another subtype.

30 (c) *Testing in Chinese hamster cell lines*

The Chinese hamster ovary cell lines expressing mGluR_{1α}, mGlu R₂ and mGluR_{4α} receptors have been described previously (Amarori and Nakanishi, Neuron 8, 757-765,

1992; Tanabe *et al.*, Neuron 8, 169-179, 1992, and J. Neurochem. 63, 2038-2047, 1993). They are maintained at 37 °C in a humidified 5% CO₂ incubator in Dubecco's Modified Eagle Medium (DMEM) containing a reduced concentration of (S)-glutamine (2mM) and are supplemented with 1% proline, penicillin (100 U/mL), streptomycin (100 mg/mL) and
5 10% dialyzed fetal calf serum (all GIBCO, Paisley). Two days before assay 1.8×10^6 cells are evenly distributed into the wells of 24 well plates.

Phosphatidylinositol (PI) hydrolysis can be measured as described previously (Hayashi *et al.*, Nature 366, 687-690, 1992, and J. Neuroscience 14, 3370-3377, 1994). Briefly, the
10 cells are labeled with [³H]inositol (2μ Ci/mL) 24 h prior to the assay. For agonist assays, the cells are incubated with test compound dissolved in phosphate-buffered saline (PBS)-LiCl for 20 min, and agonist activity is determined from the level of ³H-labeled mono-, bis- and tris-inositol phosphates generated, as measured following ion-exchange chromatography, compared with the level generated in the absence of the test compound.
15 For antagonist assays, the cells are preincubated with ligand dissolved in PBS-LiCl for 20 min prior to incubation with test compound and 10 μ M (S)-Glu for 20 min. The antagonist activity is then determined as the inhibitory effect of the (S)-Glu mediated response.

20 The assay of cyclic AMP formation can be performed as described previously (Hayashi *et al.*, 1992, 1994). Briefly, the cells are incubated for 10 min in PBS containing test compound and 10 μ M forskolin and 1 mM 3-isobutyl-1-methylxanthine (IBMX) (both Sigma, St. Louis, MO, USA). The agonist activity is then determined as the inhibitory effect on the forskolin-induced cyclic AMP formation. For antagonist assay, the cells are
25 preincubated with ligand dissolved in PBS containing 1 mM IBMX for 20 min prior to a 10 min incubation in PBS containing test compound, 20 μ M(mGlu2) or 50 μ M (mGlu4a) (S)-Glu, 10 μ M forskolin and 1 mM IBMX. The antagonist activity is then determined as the potentiating effect on the forskolin-induced cyclic AMP formation.

30 *In Vivo Testing:*

In vivo testing for demonstration of the pharmacological activity of certain compounds on representative mGlu receptor subtypes can be performed using Sprague Dawley rat tissues.

Phosphatidylinositol (PI) hydrolysis can be measured as described below:

Briefly, cross-chopped slices are prepared from neonatal Sprague Dawley rat tissue (age: p7-p14). The slices are pre-labelled with [³H] myo-inositol. Following pre-labelling, the
5 slices are incubated with the test drugs and standard (known Group I agonists *i.e.* ACPD) for a period of 45 minutes. The incubation is terminated by the addition of chloroform/methanol/HCl (100:200:2). The resulting mixture is separated into two phases by the addition of chloroform and distilled water. The aqueous fraction is applied to ion exchange columns, and inositol phosphates are eluted using 800 mM Ammonium
10 Formate/100 mM Formic Acid. The eluent is then analyzed using liquid scintillation counting. The amount of inositol phosphate accumulation is expressed as a percentage of that induced by ACPD.

The assay of cyclic AMP formation can be performed as described previously (Tovey *et al.*, *Clinica Chimica Acta*, 56, 221-234, 1974). The assay can be modelled on the cyclic
15 AMP assay kit available from Amersham, which in turn, is based on the assay created by Tovey *et al.* Briefly, samples are prepared from Sprague Dawley rat (225-250g) cortical slices. Slices are incubated with the drug, and then challenged with forskolin to induce cyclic AMP release. Following termination of the reaction by boiling, the slices are
20 homogenized and centrifuged. Samples of supernatant are then incubated for 2-3 hours with a known quantity of [³H]cAMP and a binding protein. When the incubation is complete, the bound cyclic AMP is separated from the free cyclic AMP by centrifugation with charcoal. The resulting supernatant (containing free cyclic AMP) is then analyzed by liquid scintillation counting. The amount of unbound cyclic AMP can be calculated from a
25 standard curve previously determined with various samples of free cyclic AMP.

In performing such experiments with some of the compounds of the present invention, it has been demonstrated that some compounds of the present invention act as modulators of the cAMP-linked metabotropic glutamate receptors, while showing less activity with
30 phosphatidylinositol-linked metabotropic glutamate receptors and *vice versa*.

Administration of Compounds of Formula (I)

According to another aspect, the present invention provides a method of modulating one or more mGluR functions in a warm-blooded mammal which comprises administering an effective amount of a compound of Formula I, or a non-toxic metabolically-labile ester or
5 amide thereof, or a pharmaceutically acceptable salt thereof.

The compounds of the present invention are preferably formulated prior to administration. Therefore, another aspect of the present invention is a pharmaceutical formulation comprising a compound of Formula I and a pharmaceutically-acceptable carrier, diluent, or
10 excipient. The present pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or
15 liquid material that acts as a vehicle, excipient, or medium for the active ingredient.

The compounds of Formula I are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These
20 compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

The present invention also provides pharmaceutical compositions containing compounds as
25 disclosed in the claims in combination with one or more pharmaceutically acceptable, inert or physiologically active, diluents or adjuvants. The compounds of the invention can be freeze-dried and, if desired, combined with other pharmaceutically acceptable excipients to prepare formulations for administration. These compositions may be presented in any form appropriate for the administration route envisaged. The parenteral and the intravenous
30 route are the preferential routes for administration.

Compounds of the general Formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein

- 5 includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition, there is provided a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier. One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and,
- 10 if desired, other active ingredients. The pharmaceutical compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- 15 Compositions intended for oral use may be prepared according to any procedure known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient
- 20 in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example
- 25 magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- 30 Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium

phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

- Aqueous suspensions contain active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methyl cellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example hepta-decaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or *n*-propyl- *p*-hydroxy benzoate, one or more colouring agents, one or more flavouring agents or one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents
5 may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and
10 flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may
15 be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or a suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
20 Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

25 The compound(s) of the general Formula I may be administered, together or separately, in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the
30 rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

Compound(s) of general Formula I may be administered, together or separately, parenterally in sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anaesthetics, preservatives and buffering agents can be dissolved in the vehicle.

5

The dosage to be administered is not subject to defined limits, but it will usually be an effective amount. It will usually be the equivalent, on a molar basis of the pharmacologically active free form produced from a dosage formulation upon the metabolic release of the active free drug to achieve its desired pharmacological and physiological effects. The compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

The active compound is effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg of body weight. A typical daily dose will contain from about 0.01 mg/kg to about 100 mg/kg of the active compound of this invention. Preferably, daily doses will be about 0.05 mg/kg to about 50 mg/kg, more preferably from about 0.1 mg/kg to about 25 mg/kg. In the treatment of adult humans, the range of about 0.1

to about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several smaller doses for administration throughout the day.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 mg to about 500 mg, more preferably about 25 mg to about 300 mg of the active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient. The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way.

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Active Ingredient	250
Starch, dried	200
Magnesium stearate	10
Total	460

The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.

Formulation 2

A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
Active Ingredient	250
Cellulose, microcrystalline	400

Silicon dioxide, fumed	10
Stearic acid	5
Total	665

The components are blended and compressed to form tablets each weighing 665 mg.

Formulation 3

- 5 An aerosol solution is prepared containing the following components:

	Weight %
Active Ingredient	0.25
Ethanol	29.75
Propellant 22 (Chlorodifluoromethane)	70.00
Total	100

- The active compound is mixed with ethanol and the mixture added to a portion of the Propellant 22, cooled to -30 °C and transferred to a filling device. The required amount is
10 then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation 4

Tablets each containing 60 mg of active ingredient are made as follows:

15

	Quantity (mg/tablet)
Active Ingredient	60
Starch	45
Microcrystalline cellulose	35
Polyvinylpyrrolidone	4
Sodium carboxymethyl starch	4.5

Magnesium stearate	0.5
Talc	1.0
Total	150

The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders that are then passed through a No. 14 mesh U.S. sieve. The granules so produced
5 are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

10

Formulation 5

Capsules each containing 80 mg medicament are made as follows:

	Quantity (mg/capsule)
Active Ingredient	80
Starch	59
Microcrystalline cellulose	59
Magnesium stearate	2
Total	200

15

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation 6

20

Suppositories each containing 225 mg of active ingredient may be made as follows:

	Quantity (mg/suppository)
Active Ingredient	225
Saturated fatty acid glycerides	2000
Total	2225

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Formulation 7

Suspensions each containing 50 mg of medicament per 5 mL dose are made as follows:

Active Ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mL
Benzoic acid solution	0.10 mL
Flavour	q.v.
Color	q.v.
Purified water to total	5 mL

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation 8

An intravenous formulation may be prepared as follows:

	Quantity
Active Ingredient	100 mg
Mannitol	100 mg
5 N Sodium hydroxide	200 mL
Purified water to total	5 mL

Formulation 9

A topical formulation may be prepared as follows:

5

	Quantity
Active Ingredient	1–10 g
Emulsifying Wax	30 g
Liquid Paraffin	20 g
White soft paraffin to	100 g

The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

10

Formulation 10

Sublingual or buccal tablets, each containing 10 mg of active ingredient, may be prepared as follows:

	Quantity (mg/tablet)
Active Ingredient	10.0
Glycerol	210.5
Water	143.0
Sodium Citrate	4.5

Polyvinyl Alcohol	26.5
Polyvinylpyrrolidone	15.5
Total	410.0

The glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90 °C. When the polymers have gone into solution, the solution is cooled to about 50 °-55 °C and
5 the medicament is slowly admixed. The homogeneous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.

- 10 Another formulation of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.

The construction and use of transdermal patches for the delivery of pharmaceutical agents
15 is well known in the art (see, for example, U.S. Pat. No. 5,023,252, issued Jun. 11, 1991) herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to
20 the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Pat. No. 5,011,472, issued Apr. 30, 1991, which is herein incorporated by reference.

25

Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs. Latentiation is generally achieved through blocking of the

hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable


to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions that can
5 transiently open the blood-brain barrier.

To gain a better understanding of the invention described herein, the following examples are set forth. It should be understood that these examples are for illustrative purposes only. Therefore they should not limit the scope of the invention in any way.

EXAMPLES

The following abbreviations are used in the Examples: EtOAc, ethyl acetate; THF, tetrahydrofuran; EtOH, ethanol; TLC, thin layer chromatography; GC, gas
15 chromatography; HPLC, high pressure liquid chromatography; Et₂O, diethyl ether; DMSO, dimethyl sulfoxide; DBU, 1,8-diazabicyclo-[5.4.0]undec-7-ene.

Example 1:



5 *Preparation of 1,2-Phenylenediacetic acid (compound 2):*

In a round-bottomed flask, fitted with a reflux condenser, 10 g of phenylenediacetonitrile and 180 g of 50% sulphuric acid were refluxed for 2 h. The reaction mixture was cooled on ice to yield (2) as white crystals. Yield 11.4 g. This compound was used without further purification.

10

Preparation of Dimethyl-1,2-phenylenediacetate (compound 3):

The diacid (2) from above was dissolved in 150 mL of methanol, saturated with HCl gas and refluxed for 2 h. The resulting solution was cooled, evaporated to dryness and the residue was taken up in 200 mL of diethyl ether. The ethereal extract was washed with
15 saturated sodium bicarbonate solution, dried over magnesium sulphate and evaporated to give crude (3). The residue was purified by flash chromatography on silica to yield 11.1 g (78%) of compound (3) from (1).

Preparation of Methyl-2-indanone-1-carboxylate (compound 4):

20 A solution of (3) (10 g) in benzene (50 mL) was placed in a round-bottomed flask together with molecular sodium (1.5 g) and stirred until no further hydrogen was given off. The resulting solution was washed with 1N HCl (50 mL), water (50 mL) and brine (50 mL), dried over magnesium sulphate and evaporated to give crude (4) which was re-crystallized from water/methanol to give 8 g (92%) of (4) as a light yellow solid.

25 ¹H NMR (CDCl₃) δ 3.18 (s, 2H, enolate), 3.59 (s, 2H), 3.79 (s, 3H, enolate), 3.97 (s, 3H), 7.05-7.62 (4H), 11.03 (s, 1H), 12.13 (s, 1H, enolate). The ratio of ketone:enolate 5.6:1.

Preparation of Ethyl-1-methoxycarbonyl-2-oxo-indaneacetate (compound 5):

30 6.02 g of compound 4 (as prepared in example 1), 9.44 mL of DBU and 7.0 mL of ethylbromoacetate was stirred in 25 mL of DMF overnight. The reaction mixture was diluted and extracted with (3 x 50 mL) of EtOAc and washed with water. The organic solution was dried over MgSO₄, filtered and evaporated. The crude mixture was purified

by flash chromatography (ethyl acetate:hexanes 10-30%:90-70%) to yield 7.1g (82%) of compound (5) as on oil.

^1H NMR (CDCl_3) δ 3.20-3.42 (AB Pattern, 2H), 3.59 (s, 3H), 3.70-3.95 (4H), 7.15-7.35 (4H).

5

Preparation of 2-oxo-indaneacetic acid (compound 6):

Compound (5) was refluxed in 60 mL of 1:1 6 N HCl:acetic for 2 h. The resulting mixture gave compound (6) on cooling, which was re-crystallized from water/methanol to yield 3.5 g (71%) of compound (6).

10 ^1H NMR (CDCl_3) δ 2.90-3.10 (m, 2H), 3.58 (s, 2H), 3.70 (m, 1H), 7.1-7.4 (4H).

Preparation of 1-indaneacetic acid-2-(5,5'-hydantoin) (compound 7):

1.9 g of the keto acid (compound 6) was dissolved in 20 mL of 1:1 EtOH: water with 1.3 g (2.0 mmol) of potassium cyanide and 3.8 g of ammonium carbonate (4.0 mmol) 15 in a sealed tube. The solution was stirred and heated to 90-100°C for 16 h. The resulting dark solution was cooled and acidified with 6 N HCl and concentrated to a residue of (7), which was extracted with ethanol, filtered and used without further purification.


Preparation of 2-amino-2-carboxyindaneacetic acid (compound 8):

20 The hydantoin (7) was placed in a round-bottomed flask and refluxed together with 45 mL of 2 N NaOH for 16 h. The resulting solution was cooled, acidified with 6 N HCl, evaporated to dryness and extracted into ethanol. The ethanolic solution was treated with propylene oxide to precipitate a mixture of crude *cis* and *trans* (8). Chromatography on Spectrum 1X4 anion exchange resin, with dilute acetic acid gave *cis* and *trans* isomers of 25 (8) as colorless crystals from methanol/water.

Cis isomer of compound (8) ^1H NMR (D_2O) δ 2.5-2.7 (m, 2H), 3.15 (d, 1H), 3.58 (d, 1H), 4.05 (m, 1H), 7.1-7.35 (m, 4H).

Trans isomer of compound (8) ^1H NMR (D_2O) δ 2.55 (dd, 1H), 2.8 (dd, 1H), 3.23 (d, 1H), 3.55 (d, 1H), 3.85 (dd, 1H), 7.15-7.3 (m, 4H).

30 Anal. Calculated for compound (8): C; 61.27, H; 5.57, N; 5.95. Found: C; 57.05, H; 5.93, N; 5.45, contains 0.9 mol of H_2O .

Example 2:**Preparation of Methyl-1-indanecarboxylate-2-(5,5'-hydantoin) (compound 9):**


1.5 g of KCN was added to solution of 5.7 g of compound 4 (prepared as described in example 1) in 50 mL of 1:1 H₂O: Ethanol in a pressure vessel. The pressure tube was sealed and the resulting mixture was stirred at 80 °C for 3 days. After the completion of the reaction [judged by TLC (CHCl₃:EtOH, 99:1)], the solution was acidified with 6N HCl and the residue after evaporation was taken up in ethanol and filtered. The ethanolic solution was evaporated to dryness and the dark sticky residue was hydrolysed without further purification.

Preparation of 2-amino-1,2-dicarboxyindane (compound 10):

The residue obtained in preparation 1 was treated with aqueous 2M NaOH in a pressure vessel and the vessel was sealed and the reaction mixture was stirred at 110 °C for 24 h. The resulting dark solution was acidified with 6M HCl and evaporated to dryness. The residue was taken up in ethanol and filtered under vacuum. The amino acid was precipitated by the addition of propylene oxide to give crude product. Purification was achieved by ion exchange chromatography to give 450 mg (8.2% from compound 4) of compound 10 as a single spot staining to ninhydrin.

¹H NMR (D₂O) δ 7.3 (s, 4H), 2.8 (s, 1H), 2.5 (s, 2H).

Anal. Calculated for compound 10: C; 59.73, H; 5.01, N; 6.33. Found: C; 53.31, H; 5.82, N; 5.45, contains 1.5 mol of H₂O.

Example 3:

5

Preparation of intermediate Compound (11):

Sodium bis(trimethylsilyl)amide was added to a stirred solution of (methoxymethyl)triphenylphosphonium chloride (9.51 g) in dry THF (80 mL) at 0 °C under N₂. The resulting solution was stirred at 0 °C for 35 min and then 4.31g of compound 4 was added a solution in THF (40 mL) over 10 min. The resulting mixture was stirred at 0 °C for 2 h and at room temperature for 1 h. The reaction was quenched with water (30 mL), and the mixture was partitioned between brine (200 mL) and EtOAc (200 mL). Organic extracts were washed with brine (2x150 mL) and the combined aqueous phases were extracted with EtOAc (3 x 150 mL). The combined organic extracts were dried and concentrated. The crude product was purified by column chromatography (hexanes: EtOAc, 9:1) to yield 3.11 g (62.8%) of compound (11).

Preparation of intermediate Compound (12):

Trimethylsilyl iodide was added to a stirred solution of compound (11) in pyridine (0.429 mL) and CHCl_3 (292 mL) under inert atmosphere. The resulting mixture was stirred for 1.5 h, followed by a further addition of 0.3 mL of trimethylsilyl iodide. The mixture was stirred for additional 40 min and then quenched with 80 mL of ice cold NaHCO_3 solution and stirred for 10 min and then poured into brine and extracted with ethyl acetate (2 x 200 mL). The resulting solution was washed with brine, dried over MgSO_4 and evaporated to obtain crude compound (12) as a gum. The crude product was purified by column chromatography (hexanes: EtOAc 8:1-85:15) to yield 1.9 g (65.3%) of compound (12).


Preparation of 2-Amino-1,2-dicarboxylic acid (compound 14):

A solution of compound (12) from above (1.9g) in 1:1 water: EtOH (20mL) was heated in a pressure vessel with 1.35 g KCN and 4.5g NH_4CO_3 at 85 °C for 2 days. The resultant dark solution was carefully acidified and reduced to dryness in *vacuo*. The crude product was extracted into EtOH and filtered. The ethanolic solution was evaporated to dryness and the crude product was hydrolyzed without further purification. The hydantoin (13) was dissolved in 20 mL of 2M NaOH and refluxed for 24 h. The resulting solution was acidified with 6M HCl and evaporated to dryness. The resulting solid was taken up in EtOH and filtered, the product was precipitated with propylene oxide to give 320 mg (14.6%) of compound (14).

^1H NMR (D_2O) δ 2.45 (t 2H), 2.85 (m 1H), 3.25 (d 1H), 4.1 (d 1H), 7.3 (s 4H).

Anal. Calculated for compound (14): C; 61.27, H; 5.57, N; 5.95. Found: C; 59.0, H; 5.73, N; 5.54, contains 0.5 mol of H_2O .

Example 4:



5 *Preparation of intermediate compound (4):*

Compound 4 can either be prepared as shown in example 1, in an alternative manner compound 4 can be prepared from compound 6 (from example 1) as shown below:

The ketoacid 6 (3.5g) was dissolved in 50 mL of methanol, saturated with HCl gas and refluxed for 2 h. The resulting solution was cooled, evaporated to dryness and the residue was taken up in 100 mL of diethyl ether. The ethereal extracts were washed with saturated sodium bicarbonate solution, dried over magnesium sulphate and evaporated to give crude 4. The residue was purified by flash chromatography on silica (ethyl acetate:hexanes 1:9-3:7) to yield 3.1 g (84%) of pure compound 4.

15

Preparation of intermediate compound (15)

Sodium bis(trimethylsilyl)amide (17.9mL) was added to a stirred suspension of (methoxy methyl)triphenylphosphonium chloride (6.4g) in dry THF (60 mL) at 0 °C under N₂. The resulting red mixture was stirred at 0 °C for 35 minutes and a solution of compound 4 (3.1g) in dry THF (40 mL) added over 10 minutes. The mixture was stirred at 0 °C for 2 h and at room temperature for 1 h. The reaction mixture was quenched with 20 mL of water and partitioned between brine (100 mL) and EtOAc (100 mL). The crude product was purified by column chromatography (hexanes: EtOAc, 9: 1) to obtain 3.01g (85%) of compound 15.

Preparation of intermediate compound (16)

To a stirred solution of compound **15** in pyridine (0.4 mL) and CHCl₃ (275 mL) at 0 °C, was added 0.3 mL of trimethylsilyl iodide under N₂. The resulting mixture was stirred for 1.5 h and a further 0.3 mL of trimethylsilyl iodide added. The mixture was stirred for 40 min and quenched with 80 mL of ice cold NaHCO₃ solution. The mixture was stirred for 10 min then poured into brine and extracted with ethyl acetate (2 x 200 mL). The resulting solution was washed with brine, dried over MgSO₄ and evaporated to give compound **16** as a gum. The material was purified by column chromatography (hexanes: EtOAc 80:10-85:15) to yield 2.21g (76.1%) of pure compound **16**.

Preparation of intermediate compound (17)

The aldehyde **16** was dissolved in 25 mL of 1:1 EtOH:water along with 1.5 g KCN and 3g (NH₄)₂CO₃. The mixture was placed in a sealed pressure vessel and heated to 85 °C for 18 h. The resulting dark mixture was carefully acidified with 6 M HCl and evaporated to dryness. The residue was extracted with EtOH, filtered and evaporated to give the crude hydantoin **17**, which was used without further purification.

Preparation of intermediate compound (18)

The crude hydantoin **17** was taken up in 20 mL of 2 M NaOH and sealed in a pressure vessel. The mixture was heated to 140 °C for 4 h and then cooled to room temperature. The mixture was acidified with 6 M HCl and evaporated to dryness. The residue was taken up in EtOH and filtered. The amino acid was obtained by precipitation with propylene oxide and filtration to give the amino acid **18** as a mixture of *cis* and *trans* isomers.

In Vivo* Testing of Exemplary Compounds:*Cyclic AMP assay:***Rationale:*

Group II/III metabotropic glutamate receptors (mGluRs) are negatively coupled to adenylyate cyclase, and agonists of these receptors lead to a decrease in intracellular cyclic AMP accumulation.

Method:

The assay has been modeled on the cyclic AMP assay kit available from Amersham. This kit, in turn, is based on the assay created by Tovey *et al.* (1974). Briefly, the samples were prepared from Sprague Dawley rat (225-250g) cortical slices. Slices were incubated with the test compound (drug), and then challenged with forskolin to induce cyclic AMP release. Following termination of the reaction by boiling, the slices were homogenized and centrifuged. Samples of supernatant were then incubated for 2-3 hours with a known quantity of [³H]cAMP and a binding protein. When the incubation was complete, the bound cyclic AMP was separated from the free cyclic AMP by centrifugation with charcoal. The resulting supernatant (containing free cyclic AMP) was then analyzed by liquid scintillation counting. The amount of unbound cyclic AMP was calculated from a standard curve previously determined with various samples of free cyclic AMP.

15 *Results Interpretation:*

If the drugs tested inhibit forskolin-induced cyclic AMP accumulation, they are considered to be Group II/III agonists. Conversely, if they inhibit the decrease in forskolin-induced cyclic AMP accumulation caused by glutamate, they are considered to be Group II/III antagonists.

20 *Results:*

Aminoindane	Group II/III Agonist	EC ₅₀ (M)	Group II/III Antagonist	EC ₅₀ (M)
<i>Cis</i> -2 amino-2-carboxyindaneacetic acid (compound 8)	No	-	Yes	1.2x10 ⁻⁹
<i>Trans</i> -2 amino-2-carboxyindaneacetic acid (compound 8)	Yes	1.1x10 ⁻⁷	No	-

Phosphatidylinositol Assay*Rationale:*

Group I metabotropic glutamate receptors (mGluRs) are positively coupled on inositol phosphate metabolism. Agonists at these receptors lead to an increase in intracellular free inositol phosphates, while antagonists inhibit the increase in intracellular free inositol phosphate induced by standard agonists (*i.e.* ACPD).

Method:

Cross-chopped slices were prepared from neonatal Sprague Dawley rat tissue (age: p7-p14). The slices were pre-labelled with [³H] myo-inositol. Following pre-labelling, the slices were incubated with the test compounds and standard (known Group I agonists *i.e.* ACPD) for a period of 45 minutes. The incubation was terminated by the addition of chloroform/methanol/HCl (100:200:2). The resulting mixture was separated into two phases by the addition of chloroform and distilled water. The aqueous fraction was applied to ion exchange columns, and inositol phosphates were eluted using 800 mM Ammonium Formate/100 mM Formic Acid. The eluent was then analyzed using liquid scintillation counting. The amount of inositol phosphate accumulation was expressed as a percentage of that induced by ACPD.

Results Interpretation:


If the drugs cause an increase in intracellular free inositol phosphate accumulation, they are considered to be Group I agonists. If they inhibit the increase in intracellular free inositol phosphate accumulation induced by ACPD, they are considered to be Group II antagonists.

Results:

Aminoindane	Group I Agonist	EC ₅₀ (M)	Group I Antagonist	EC ₅₀ (M)
<i>Cis</i> -2-amino-2-carboxyindaneacetic acid (compound 8)	No	-	Yes	2.2x10 ⁻⁶
<i>Trans</i> -2-amino-2-carboxyindaneacetic acid (compound 8)	No	-	Yes	1.6x10 ⁻³

**EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY
PREVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:**

1. A compound having structural formula (I):



stereoisomers thereof, or pharmaceutically acceptable salts or hydrates thereof,
wherein:

R1, and **R2** are selected from the group comprising:

- (i) H
- (ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfino, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, where $n = 1, 2, 3, 4, 5$, or 6 ;

X is an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol.


Y is a basic group selected from the group comprising 1° amino, 2° amino, 3° amino, quaternary ammonium salts, aliphatic 1° amino, aliphatic 2° amino, aliphatic 3° amino, aliphatic quaternary ammonium salts, aromatic 1° amino, aromatic 2°

amino, aromatic 3° amino, aromatic quaternary ammonium salts, imidazol, guanidino, boronoamino, allyl, urea, thiourea ;

m is 0, 1.

R4, R5, R6, R7 are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or an acceptable ester thereof.

2. A compound as claimed in claim 1, wherein **R1** can be H, CO₂H, CH₂CO₂H.
3. A compound as claimed in claim 1, wherein **R2** can be H, CO₂H, CH₂CO₂H.
4. A compound according to claim 1, wherein, **m** = 0, **R1** is CH₂COOH, **R2** = **R3** = **R4** = **R5** = **R6** = H, **X** is COOH, **Y** is NH₂.
5. A compound according to claim 1, wherein, **m** = 0, **R1** is COOH, **R2** = **R3** = **R4** = **R5** = **R6** = H, **X** is COOH, **Y** is NH₂.
6. A compound according to claim 1, wherein, **m** = 1, **R1** is COOH, **R2** = **R3** = **R4** = **R5** = **R6** = H, **X** is COOH, **Y** is NH₂.
7. A compound according to claim 1, wherein, **m** = 1, **R1** is CH₂COOH, **R2** = **R3** = **R4** = **R5** = **R6** = H, **X** is COOH, **Y** is NH₂.
8. A process for the preparation of a compound of Formula I, or a pharmaceutically acceptable metabolically-labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which comprises:
 - a) hydrolyzing a compound of formula (IIa) or (IIb):




wherein: **R1**, and **R2** are selected from the group comprising:

- i) H
- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfino, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, wherein $n=1, 2, 3, 4, 5$, or 6 ;


R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof, **R7** is a hydrogen atom or an acyl group. Preferred functional groups for **R7** are hydrogen and (2-6C) alkanoyl groups, such as acetyl; or

- b) hydrolyzing a compound of formula (IIIa) or (IIIb):



(IIIa)


or



(IIIb)


wherein: **R1**, **R2**, **R3**, **R4**, **R5** and **R6** are as defined above, **R8** and **R9** are each independently represent a hydrogen atom, a (C₂-C₆) alkanoyl group, a (C₁-C₄) alkyl group, a (C₃-C₄) alkenyl group or a phenyl (C₁-C₄) alkyl group wherein the phenyl is unsubstituted or substituted by halogen, (C₁-C₄) alkyl or (C₁-C₄) alkoxy, or a salt thereof; or

c) deprotecting a compound of formula (IVa) or (IV b):



(IVa)

or




(IVb)

wherein: **R1**, **R2**, **R3**, **R4**, **R5** and **R6** are as defined above and **R10** is a hydrogen atom or a carboxyl protecting group, or a salt thereof, and **R11** represents a hydrogen atom or a nitrogen protecting group;


whereafter, if necessary and/or desired, the following steps are carried out:

- i) resolving the compound of Formula I;
 - ii) converting the compound of Formula I into a non-toxic metabolically labile ester or amide thereof and/or;
 - iii) converting the compound of Formula I or a non-toxic metabolically labile ester or amide thereof into a pharmaceutically acceptable salt thereof.
9. A pharmaceutical formulation, which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
10. A use of the compound of structural formula (I) as claimed in claim 1, in modulating one or more metabotropic glutamate receptor functions in warm blooded mammals, wherein said use comprises administering an effective amount of a compound of formula (I).
11. A use of the compound of structural formula (I) as claimed in claim 1, in treating a neurological disease or disorder selected from the group comprising: cerebral deficits subsequent to cardiac bypass surgery and grafting, cerebral ischemia, stroke, cardiac arrest, spinal cord trauma, head trauma, perinatal hypoxia, and hypoglycemic neuronal damage, Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, AIDS-induced dementia, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms, convulsions, migraine headaches, urinary incontinence, psychosis, drug tolerance, withdrawal, and cessation (i.e. opiates, benzodiazepines, nicotine, cocaine, or ethanol), smoking cessation, anxiety and related disorders (e.g. panic attack), emesis, brain edema, chronic pain, sleep disorders, Tourette's syndrome, attention deficit disorder, and tardive dyskinesia, wherein said use comprises administering an effective amount of a compound of formula (I).

12. A use of the compound of structural formula (I), as claimed in claim 1, in treating a psychiatric disease or disorder selected from the group comprising: schizophrenia, anxiety and related disorders (e.g. panic attack), depression, bipolar disorders, psychosis, and obsessive compulsive disorders, wherein said use comprises administering an effective amount of a compound of formula (I).
13. The use according to any one of claims 7, 8 and 9 wherein said compound is selected from the group of compounds comprising :



14. A compound of formula (IIa):




wherein: wherein: **R1**, and **R2** can each separately be selected from the group consisting of:

- i) H
- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfinio, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfinio, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, where $n = 1, 2, 3, 4, 5$, or 6 ;

R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof, **R7** is a hydrogen atom or an acyl group. Preferred functional groups for **R7** are hydrogen and (2-6C) alkanoyl groups, such as acetyl; or

15. A compound of formula (IIIa):




wherein: wherein: **R1**, and **R2** can each separately be selected from the group consisting of:

- i) H

- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfinio, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfinio, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, wherein $n = 1, 2, 3, 4, 5$, or 6 ;

R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof; **R8** and **R9** are each independently represent a hydrogen atom, a (C_2-C_6) alkanoyl group, a (C_1-C_4) alkyl group, a (C_3-C_4) alkenyl group or a phenyl (C_1-C_4) alkyl group wherein the phenyl is unsubstituted or substituted by halogen, (C_1-C_4) alkyl or (C_1-C_4) alkoxy, or a salt thereof or:

16. A compound of formula (IVa):




wherein: wherein: wherein: **R1**, and **R2** can each separately be selected from the group consisting of:

- i) H
- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfinio, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, -

$(\text{CH}_2)_n$ -sulfonyl, $(\text{CH}_2)_n$ -sulfinyl, $(\text{CH}_2)_n$ -boronyl, $(\text{CH}_2)_n$ -tetrazolyl, and $(\text{CH}_2)_n$ -isoxazolyl, wherein $n = 1, 2, 3, 4, 5$, or 6 ;

R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof; **R10** is a hydrogen atom or a carboxyl protecting group, or a salt thereof, and **R11** is a hydrogen atom or a nitrogen protecting group.

17. A compound of formula (IIb):




wherein: wherein: wherein: **R1**, and **R2** can each separately be selected from the group consisting of:

- i) H
- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfonyl, sulfinyl, boronyl, tetrazolyl, isoxazolyl, $(\text{CH}_2)_n$ -carboxy, $(\text{CH}_2)_n$ -phosphono, $(\text{CH}_2)_n$ -phosphino, $(\text{CH}_2)_n$ -sulfonyl, $(\text{CH}_2)_n$ -sulfinyl, $(\text{CH}_2)_n$ -boronyl, $(\text{CH}_2)_n$ -tetrazolyl, and $(\text{CH}_2)_n$ -isoxazolyl, wherein $n = 1, 2, 3, 4, 5$, or 6 ;

R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof; **R7** is a hydrogen atom or an acyl

group. Preferred functional groups for **R7** are hydrogen and (2-6C) alkanoyl groups, such as acetyl.

18. A compound of formula (IIIb):




wherein: wherein: wherein: **R1**, and **R2** can each separately be selected from the group consisting of:

- i) H
- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfinio, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfinio, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, wherein $n = 1, 2, 3, 4, 5$, or 6 ;

R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof; **R8** and **R9** are each independently represent a hydrogen atom, a (2-6C) alkanoyl group, a (1-4C) alkyl group, a (3-4C) alkenyl group or a phenyl (1-4C) alkyl group wherein the phenyl is unsubstituted or substituted by halogen, (1-4C) alkyl or (1-4C) alkoxy, or a salt thereof or:

19. A compound of formula (IVb):



wherein: wherein: wherein: **R1**, and **R2** can each separately be selected from the group consisting of:

- i) H
- ii) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfinio, borono, tetrazol, isoxazol, $-(CH_2)_n$ -carboxy, $-(CH_2)_n$ -phosphono, $-(CH_2)_n$ -phosphino, $-(CH_2)_n$ -sulfono, $-(CH_2)_n$ -sulfinio, $-(CH_2)_n$ -borono, $-(CH_2)_n$ -tetrazol, and $-(CH_2)_n$ -isoxazol, wherein $n=1, 2, 3, 4, 5$, or 6 ;

R3, **R4**, **R5** and **R6** are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl, or pharmaceutically acceptable ester or salt thereof; **R10** is a hydrogen atom or a carboxyl protecting group or a salt thereof, and **R11** is a hydrogen atom or a nitrogen protecting group.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/CA 00/00770

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C229/50 C07C229/36 A61K31/195 A61K31/196 A61P25/28
 C07C255/47 C07C255/42 C07C255/44 C07D235/02 C07D233/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 15099 A (NOVO NORDISK) 23 May 1996 (1996-05-23) page 4, line 12 -page 11, line 28; claims; examples 1,2 ----	1-19
X	WO 98 51687 A (FUJISAWA PHARMACEUTICAL) 19 November 1998 (1998-11-19) page 50, preparation 47 ----	19
X	WO 97 09346 A (CORTECH) 13 March 1997 (1997-03-13) example III ----	1-3, 19
X	EP 0 515 681 A (FUJISAWA PHARMACEUTICAL) 2 December 1992 (1992-12-02) page 18, line 51 -page 20, line 23 ----- -/-	1-3, 16

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 October 2000

Date of mailing of the international search report

07/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Zervas, B

INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/CA 00/00770

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 189 203 A (ABBOTT LABORATORIES) 30 July 1986 (1986-07-30) example 99 ----	16
X	EP 0 451 753 A (ASTA PHARMA) 16 October 1991 (1991-10-16) example 44 ----	14
X	ROGER M. PINDER ET AL.: "2-Aminoindan-2-carboxylic Acids. Potential Tyrosine Hydroxylase Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY., vol. 14, no. 9, 1971, pages 892-893, XP002150544 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 page 893; tables I,,II ----	1-3,8,9, 15,16
X	R. LOHMAR ET AL.: " alpha-Aminosäuren als Nukleophile Acyläquivalente, IV. Synthese Symmetrischer Ketone unter Verwendung von 2-Phenyl-2-oxazolin-5-on" CHEMISCHE BERICHTE, vol. 113, 1980, pages 3706-3715, XP002150545 WEINHEIM DE page 3714, line 3 - line 7 ----	16
X	RUDOLF KNORR ET AL.: "Azomethine, 1-Azaallyl-Anionen und Metastabile sek. Enamine" CHEMISCHE BERICHTE, vol. 113, 1980, pages 2462-2489, XP002150546 WEINHEIM DE page 2486, line 11 - line 18 ----	14
X	US 3 532 744 A (HORACE FLETCHER III ET AL.) 6 October 1970 (1970-10-06) claims; examples 1,3 ----	1-3,8,15
X	CHEMICAL ABSTRACTS, vol. 58, no. 13, 24 June 1963 (1963-06-24) Columbus, Ohio, US; abstract no. 13935g, A. B. MAUGER ET AL.: "Aryl 2-Haloalkyl Amines. XX. The Preparation and Properties of Some Bis(2-chlorethyl)aminoaryl-substituted Hydantoins and Related Amino Acids" XP002150547 abstract & BIOCHEM. PHARMACOL., vol. 11, 1962, pages 847-858, ----	15

-/--

Patent provided by Sughrue Mion, PLLC - <http://www.sughrue.com>

INTERNATIONAL SEARCH REPORT

Int'l. Application No.

PCT/CA 00/00770

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 916 920 A (ELI LILLY) 29 June 1999 (1999-06-29) claims; examples -----	1,9-13
A	EP 0 807 621 A (LILLY INDUSTRIES) 19 November 1997 (1997-11-19) claims; examples -----	1,9-13

Patent provided by Sughrue Mion, PLLC - <http://www.sughrue.com>

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210


Continuation of Box I.2

Claims Nos.: 1(in part)-3(in part), 8(in part)- 12(in part), 14(in part)-19(in part)

Present claims 1 - 3, 8 - 12 and 14 - 19 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds according to one of the general formulas, wherein R1 and R2 are H, -COOH or -CH₂-COOH, X is a carboxy group or protected carboxy group and Y is an amino group or protected amino group.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

F_{om}
PCT



INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/00770

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 189203 A		NZ 218936 A	27-10-1989
EP 451753 A	16-10-1991	AU 7424491 A	17-10-1991
		CA 2040123 A	11-10-1991
		DE 4111249 A	06-02-1992
		FI 911698 A	11-10-1991
		HU 57788 A	30-12-1991
		JP 7112994 A	02-05-1995
		MC 2223 A	02-02-1993
		NO 911373 A	11-10-1991
		NO 924063 A	11-10-1991
		NO 924064 A	11-10-1991
		NZ 237443 A	25-11-1993
		PT 97294 A	31-01-1992
		US 5194644 A	16-03-1993
		US 5238955 A	24-08-1993
		ZA 9102630 A	29-01-1992
US 3532744 A	06-10-1970	NONE	
US 5916920 A	29-06-1999	AU 703093 B	18-03-1999
		AU 7731096 A	05-06-1997
		BR 9611521 A	29-06-1999
		CA 2237598 A	22-05-1997
		CN 1202103 A	16-12-1998
		EA 980380 A	29-10-1998
		EP 0774455 A	21-05-1997
		JP 2000500752 T	25-01-2000
		WO 9717950 A	22-05-1997
EP 807621 A	19-11-1997	CA 2204846 A	13-11-1997
		JP 10067723 A	10-03-1998
		US 5863947 A	26-01-1999

Patent provided by Sughrue Mion, PLLC - <http://www.sughrue.com>